Abstract
The authors on the basis of analytical review of the world literature analyzed the pharmacological activity of melatonin in the aspect of clinical use in COVID-19. Melatonin is traditionally considered a hormone of the pineal gland, which provides the interaction of organism with environment for information about the light regime of the environment. Until recently, the main scope of this drug was various sleep disorders. However, subsequent studies revealed that the melatonin’s ability to exert anticonvulsant, antidepressant, antineoplastic, neuroprotective, antioxidant and anti-gonadotropic effect and have some therapeutic activity for pharmacotherapy of tinnitus, migraine, neurodegenerative diseases, epilepsy, breast cancer, diseases of the respiratory and cardiovascular systems.The article found that a valuable effect of melatonin is its ability to reduce the release of proinflammatory cytokines, thereby reducing the intensity of inflammation and «cytokine storm» in patients with COVID-19.The paper notes that melatonin’s role as antioxidant, reduce the risk of oxidative stress during inflammation, but also as a factor of prevention of the development of «cytokine storm», with the development of which is associated with high risks of mortality at COVID-19. Melatonin is effective in patients hospitalized with COVID-19 by reducing vascular permeability, levels of General anxiety, use of sedatives and improve sleep quality.Found that melatonin can be used in combination with drugs and therapies COVID-19. For example, melatonin and alpha-lipoic acid may decrease kidney damage from oxidative stress caused by a combination of antiviral medications lopinavir/ritonavir. Using melatonin to mitigate medical and social problems in the context of a global pandemic may be substantial and socially responsible measure to preserve and maintain the health of the population.The authors found that the pharmacological activity of melatonin in the aspect of clinical use in COVID-19 is associated with its antioxidant and anti-stress activity that can be used effectively in conditions of coronavirus infection.
Highlights
The authors on the basis of analytical review of the world literature analyzed the pharmacological activity of melatonin in the aspect of clinical use in COVID-19
The article found that a valuable effect of melatonin is its ability to reduce the release of proinflammatory cytokines, thereby reducing the intensity of inflammation and «cytokine storm» in patients with COVID-19
The paper notes that melatonin’s role as antioxidant, reduce the risk of oxidative stress during inflammation, and as a factor of prevention of the development of «cytokine storm», with the development of which is associated with high risks of mortality at COVID-19
Summary
Авторами статьи на основании аналитического обзора мировой литературы проанализирована фармакологическая активность мелатонина в аспекте клинического применения при COVID-19. Что фармакологическая активность мелатонина в аспекте клинического применения при COVID-19 связана с его антиоксидантной и антистрессовой активностью, что может быть эффективно использовано в условиях коронавирусной инфекции. Цель работы – на основании аналитического обзора мировой литературы проанализировать фармакологическую активность мелатонина в аспекте клинического применения при COVID-19. У 3–4% пациентов зарегистрировано развитие острого респираторного дистресс-синдрома (ОРДС) и острое повреждение легких (ARDS/ALI). Возможности медикаментозной терапии Сообщалось, что при COVID-19 успешно применяется препарат Remdesivir – ингибитор РНК-зависимой РНКполимеразы (RdRP), который в 2019 году был разработан биофармацевтической компанией «Gilead Sciences» (Фостер-сити, Калифорния, США) для лечения вирусов гриппа и лихорадки Эбола. В 2020 году экспериментальный препарат Remdesivir был одобрен FDA (США) для применения в экстренных случаях при коронавирусной инфекции COVID-19. Что на своем сайте ГЭЦ МЗ Украины отмечает, что «проект создан с целью
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
